HAISCO PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.12 CNY | -1.67% |
|
-0.79% | +30.11% |
| 04-19 | Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 04-18 | Haisco Pharmaceutical Gets Nod to Trial HSK16149 Capsules | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 21,777 | 18,638 | 21,747 | 23,695 | 25,545 | 33,236 | - | - |
| Enterprise Value (EV) 1 | 21,777 | 18,638 | 21,747 | 23,695 | 25,545 | 33,236 | 33,236 | 33,236 |
| P/E ratio | 43.3 x | 30.2 x | 63.8 x | 85.6 x | 85.7 x | 60.2 x | 53.3 x | 24.3 x |
| Yield | - | - | - | - | 0.86% | - | 0.25% | - |
| Capitalization / Revenue | 5.53 x | 5.59 x | 7.84 x | - | 7.61 x | 8.57 x | 6.51 x | 4.95 x |
| EV / Revenue | 5.53 x | 5.59 x | 7.84 x | - | 7.61 x | 8.57 x | 6.51 x | 4.95 x |
| EV / EBITDA | - | 23.1 x | 31.4 x | - | 48.3 x | 47.5 x | 30.4 x | 20.6 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | 6.46 x | 7.73 x | - | 6.17 x | 7.05 x | 6.8 x | 4.77 x |
| Nbr of stocks (in thousands) | 1,069,612 | 1,063,821 | 1,066,028 | 1,064,949 | 1,103,460 | 1,103,460 | - | - |
| Reference price 2 | 20.36 | 17.52 | 20.40 | 22.25 | 23.15 | 30.12 | 30.12 | 30.12 |
| Announcement Date | 20-02-28 | 21-02-26 | 22-04-26 | 23-04-17 | 24-04-19 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,938 | 3,337 | 2,773 | - | 3,355 | 3,876 | 5,104 | 6,709 |
| EBITDA 1 | - | 805.9 | 691.9 | - | 529.1 | 699 | 1,093 | 1,616 |
| EBIT 1 | - | 692.2 | 512.3 | - | 313.5 | 600 | 996 | 1,532 |
| Operating Margin | - | 20.74% | 18.47% | - | 9.35% | 15.48% | 19.52% | 22.83% |
| Earnings before Tax (EBT) 1 | - | 688 | 510.7 | - | 302.5 | 600 | 996 | 1,532 |
| Net income 1 | - | 618.4 | 345.1 | 277 | 295.1 | 552 | 633 | 1,379 |
| Net margin | - | 18.53% | 12.44% | - | 8.8% | 14.24% | 12.4% | 20.55% |
| EPS 2 | 0.4700 | 0.5800 | 0.3200 | 0.2600 | 0.2700 | 0.5000 | 0.5650 | 1.240 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | 0.2000 | - | 0.0750 | - |
| Announcement Date | 20-02-28 | 21-02-26 | 22-04-26 | 23-04-17 | 24-04-19 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|
| Net sales 1 | 971.1 | 752.1 | 954 | 1,182 | 1,279 |
| EBITDA | - | - | - | - | - |
| EBIT | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS 2 | 0.0900 | 0.0800 | 0.0600 | 0.0800 | 0.0600 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 24-04-19 | 24-04-19 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 23.4% | 12.3% | - | 9.19% | 11.6% | 12.6% | 19.6% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | 7.9% | 7.9% | 14.6% |
| Assets 1 | - | - | - | - | - | 6,987 | 8,013 | 9,445 |
| Book Value Per Share 2 | - | 2.710 | 2.640 | - | 3.750 | 4.270 | 4.430 | 6.310 |
| Cash Flow per Share 2 | - | 0.1900 | 0.0300 | - | 0.4000 | 0.4000 | 0.4600 | 0.9700 |
| Capex 1 | - | 600 | 703 | - | 387 | 66 | - | - |
| Capex / Sales | - | 17.98% | 25.33% | - | 11.53% | 1.7% | - | - |
| Announcement Date | 20-02-28 | 21-02-26 | 22-04-26 | 23-04-17 | 24-04-19 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
30.12
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.11% | 4.68B | |
| +32.95% | 700B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B | |
| -1.81% | 157B |
- Stock Market
- Equities
- 002653 Stock
- Financials Haisco Pharmaceutical Group Co., Ltd.